We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme.
Massaccesi, M., Ferro, M., Cilla, S., Balducci, M., Deodato, F., Macchia, G., Valentini, V., Morganti, A. G., Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1), <<INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY>>, 2013; 18 (5): 784-791. [doi:10.1007/s10147-012-0462-0] [http://hdl.handle.net/10807/52299]
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)
Massaccesi, Mariangela;Ferro, Milena;Cilla, Savino;Balducci, Mario;Deodato, Francesco;Macchia, Gabriella;Valentini, Vincenzo;Morganti, Alessio Giuseppe
2013
Abstract
We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
